Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease

Research output: Contribution to journalReview articlepeer-review


Purpose of Review: Chronic inflammation is a major contributor to cardiovascular disease (CVD) risk. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived glycoprotein that is strongly associated with atherosclerotic disease. This review summarizes evidence on suPAR’s role in CVD pathogenesis and its potential as a prognostic indicator and therapeutic target. Recent Findings: Clinical, genetic, and experimental evidence supports suPAR’s role as a pathogenic factor in atherosclerosis. suPAR promotes atherosclerosis through modulation of monocyte activation and function. Clinically, elevated suPAR levels are linked to increased cardiovascular risk across diverse populations. Ongoing clinical trials are evaluating therapies targeting suPAR signaling. Summary: Current evidence positions suPAR as a regulator of myeloid cell function that contributes to vascular inflammation and subsequent cardiovascular events. Additional research is needed to determine whether suPAR measurement can improve CVD risk prediction and enable personalized management. Overall, suPAR is a promising immune-derived biomarker and target for reducing inflammation and cardiovascular risk.

Original languageEnglish (US)
Pages (from-to)1797-1810
Number of pages14
JournalCurrent Cardiology Reports
Issue number12
StatePublished - Dec 2023
Externally publishedYes


  • Cardiovascular disease
  • Inflammation
  • Outcomes
  • Residual risk
  • suPAR

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease'. Together they form a unique fingerprint.

Cite this